TAVR | tctmd.com

Presentation TCT 2020

SOLVE TAV - A 2x2 Randomized Trial of Self-Expandable vs Balloon-Expandable Valves and General vs Local Anesthesia in Patients Undergoing Transcatheter Aortic Valve Implantation: 1-year Results

Presenter: Hans-Josef Feistritzer

October 16, 2020

News Conference News TCT 2020

Large Databases Hint at Sentinel Benefit During TAVR, but Uncertainty Remains

By Todd Neale

October 16, 2020

07:39

REFLECT II: A Randomized Trial of a Cerebral Embolic Protection Device During TAVR

News Conference News TCT 2020

Efficacy Eludes TriGUARD 3 Cerebral Protection Device: REFLECT II

By Todd Neale

October 15, 2020

Presentation TCT 2020

Comparison of self-expanding bioprostheses for transcatheter aortic valve replacement in patients with symptomatic severe aortic stenosis: the SCOPE II randomised clinical trial

Presenter: Corrado Tamburino

October 15, 2020

News Conference News TCT 2020

Valve Disease Plus COVID-19 Often a Lethal Combination, Registry Shows

By Caitlin E. Cox

October 14, 2020

News Daily News

PARTNER Data Back 5-Year Durability of Sapien 3 TAVR

By Caitlin E. Cox

October 12, 2020

Podcast Heart Sounds

Aspirin Alone After TAVR Supported by Meta-analysis

By Todd Neale

September 29, 2020

News Daily News

Renal Function Gains Seen in CKD Patients After TAVR

By L.A. McKeown

September 15, 2020

Subscribe to TAVR

Advertisement

SOLVE TAV - A 2x2 Randomized Trial of Self-Expandable vs Balloon-Expandable Valves and General vs Local Anesthesia in Patients Undergoing Transcatheter Aortic Valve Implantation: 1-year Results

Large Databases Hint at Sentinel Benefit During TAVR, but Uncertainty Remains

REFLECT II: A Randomized Trial of a Cerebral Embolic Protection Device During TAVR

Efficacy Eludes TriGUARD 3 Cerebral Protection Device: REFLECT II

Comparison of self-expanding bioprostheses for transcatheter aortic valve replacement in patients with symptomatic severe aortic stenosis: the SCOPE II randomised clinical trial

Valve Disease Plus COVID-19 Often a Lethal Combination, Registry Shows

PARTNER Data Back 5-Year Durability of Sapien 3 TAVR

Top Stories in Cardiology: September 2020

Aspirin Alone After TAVR Supported by Meta-analysis

Renal Function Gains Seen in CKD Patients After TAVR

Advertisement

REFLECT II: A Randomized Trial of a Cerebral Embolic Protection Device During TAVR

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content